Wells Fargo & Company Initiates Coverage on Keros Therapeutics (NASDAQ:KROS)

Key Points

• Wells Fargo & Company has initiated coverage on Keros Therapeutics (NASDAQ: KROS) with an "overweight" rating and a target price of $26.00, suggesting a potential upside of 88.00% from its current price.
• Keros Therapeutics recently reported earnings of ($0.76) per share, exceeding analysts' estimates, while the company had a significant revenue increase of 49002.7% compared to the same quarter last year.
• Insider major shareholders sold a total of 10,176,595 shares of Keros Therapeutics on October 15th, raising concerns about insider confidence in the company.

Investment analysts at Wells Fargo & Company started coverage on shares of Keros Therapeutics (NASDAQ:KROS - Get Free Report) in a research note issued on Monday,Briefing.com Automated Import reports. The firm set an "overweight" rating and a $26.00 price target on the stock. Wells Fargo & Company's target price would suggest a potential upside of 88.00% from the company's current price.

A number of other equities analysts also recently weighed in on the stock. HC Wainwright lowered their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Weiss Ratings restated a "sell (d)" rating on shares of Keros Therapeutics in a research report on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Keros Therapeutics has an average rating of "Hold" and a consensus price target of $30.00.

Keros Therapeutics Stock Up 0.7%

NASDAQ KROS opened at $13.83 on Monday. The company has a market cap of $561.77 million, a price-to-earnings ratio of 44.61, a price-to-earnings-growth ratio of 1.78 and a beta of 0.97. Keros Therapeutics has a twelve month low of $9.12 and a twelve month high of $72.37. The business's fifty day moving average is $15.28 and its 200 day moving average is $14.28.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.38. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $3.83 million. During the same period in the previous year, the business posted ($1.25) earnings per share. The business's quarterly revenue was up 49002.7% compared to the same quarter last year. On average, research analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Keros Therapeutics news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the business's stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $84,975,125.25. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the firm's stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $95,659,436.00. The disclosure for this sale can be found here. 22.90% of the stock is owned by insiders.

Institutional Trading of Keros Therapeutics

A number of large investors have recently added to or reduced their stakes in KROS. CWM LLC increased its stake in shares of Keros Therapeutics by 10,157.7% during the 1st quarter. CWM LLC now owns 2,667 shares of the company's stock worth $27,000 after purchasing an additional 2,641 shares during the last quarter. Farther Finance Advisors LLC purchased a new stake in Keros Therapeutics in the third quarter worth $47,000. Tower Research Capital LLC TRC raised its stake in shares of Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company's stock valued at $42,000 after buying an additional 1,888 shares during the period. Police & Firemen s Retirement System of New Jersey lifted its position in shares of Keros Therapeutics by 29.7% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company's stock valued at $110,000 after buying an additional 1,892 shares during the last quarter. Finally, New York State Common Retirement Fund grew its stake in shares of Keros Therapeutics by 264.1% during the 2nd quarter. New York State Common Retirement Fund now owns 10,616 shares of the company's stock worth $142,000 after acquiring an additional 7,700 shares during the period. Hedge funds and other institutional investors own 71.56% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.